API
< Back to situation

[REVISION HISTORY]

Italian Association of Medical Oncology advocacy

8 recorded revisions of this situation.

What changed

2026-11-16 12:21 UTC → 2026-11-16 12:48 UTC · added removed

The Italian Association of Medical Oncology (Aiom) has addressed two primary areas of concern regarding cancer care and prevention. First, the organization called for healthcare budgets that are commensurate with patient needs to ensure access to new medical research and treatments. Aiom warned that evaluating oncology spending solely by comparing it to previous years, while imposing reductions despite stable or increasing patient numbers, risks creating unrealistic budget goals. The association noted that while oncologists manage clinical choices, institutional spending caps and medicine prices are determined at corporate levels, cautioning against placing the burden of rising costs on medical professionals through prescription revisions. Second, Aiom president Massimo Di Maio cautioned against indiscriminate cancer testing for healthy, asymptomatic individuals, noting that non-targeted checks can lead to false positives and unnecessary costs. Recent data presented at the XXVIII Aiom National Congress in Rome, conducted alongside the Italian Federation of Healthcare Companies and Hospitals (Fiaso), highlights growing professional challenges, including high rates of burnout and workplace hostility. During the same congress, Aiom officials highlighted a crisis in independent, non-profit clinical research. Massimo Di Maio emphasized that while industry-sponsored trials are vital, independent academic research is essential for optimizing therapy use and comparing treatments. Data from 2024 shows that non-profit clinical studies in Italy account for only 6.4% of those authorized by the Italian Medicines Agency (Aifa). Obstacles include rising costs, procedural complexity, and regulatory hurdles that prevent researchers from studying alternative dosages of drugs already reimbursed by the National Health Service. Additionally, Francesco Perrone, president of New survey data from the Aiom Foundation, noted a gap in patient awareness involving 752 patients and caregivers, highlights significant knowledge gaps regarding precision oncology, such as oncology in breast cancer treatment. Findings show that only 32% of respondents are aware of liquid biopsies biopsies, 43% are unfamiliar with targeted therapies, and 24% understand the role of Molecular Tumor Boards.

Versions

  1. 2026-11-16 12:48 UTC Italian Association of Medical Oncology advocacy
  2. 2026-11-16 12:21 UTC Italian Association of Medical Oncology advocacy
  3. 2026-11-15 17:44 UTC Italian Association of Medical Oncology advocacy
  4. 2026-11-15 16:25 UTC Italian Association of Medical Oncology advocacy
  5. 2026-11-15 16:25 UTC Italian Association of Medical Oncology advocacy
  6. 2026-11-15 14:38 UTC Italian Association of Medical Oncology advocacy
  7. 2026-11-15 11:16 UTC Italian Association of Medical Oncology advocacy
  8. 2026-11-14 12:47 UTC Italian Association of Medical Oncology advocacy
  9. 2026-11-13 16:19 UTC Italian Association of Medical Oncology advocacy

Select a version to see what changed compared to the one before it.